Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that its Chief Scientific Officer, Dr. Arun Upadhyay, will be a featured speaker at the prestigious 4th Annual Dry AMD Therapeutic …
Ocugen’s Chief Scientific Officer to Speak at the 4th Annual Dry AMD Therapeutic Development Summit Read More MALVERN, PA — Ocugen, Inc. ((NASDAQ: OCGN) announced that it will host a conference call and live webcast to discuss the Company’s third quarter 2023 financial results and provide a …
Ocugen to Host Conference Call to Discuss Business Updates and Third Quarter 2023 Financial Results Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, will conduct …
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the 2023 Cell & Gene Meeting on …
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa Read More MALVERN, PA — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research, Development and Medical, will be among the …
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder and Dr. Huma Qamar, MPH, CMI, Head of Clinical Development and Medical …
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company, announced that Connie Collingsworth, former Chief Operating Officer of the Bill and Melinda Gates Foundation, will join the Company’s Business …
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board Read More MALVERN, PA — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a panel at …
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023 Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company, announced a clinical study update for Retinitis Pigmentosa (RP) participants treated in the Phase 1/2 trial to assess the safety …
Promising Update: Ocugen’s Gene Therapy for Retinitis Pigmentosa Shows Positive Results in Phase 1/2 Trial Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week reported second quarter 2023 financial results along with a general business update.
Ocugen Provides Business Update with Second Quarter 2023 Financial Results Read More